Drugs Made In America Acquisition Corp. (DMAA)
Nasdaq · Blank Checks
What they're doing
Between 2026-08-02 and 2026-10-31, public records show 2 signals for Drugs Made In America Acquisition Corp.. Most notable: 2026-09-14: Filed 8-K disclosing material agreement; 2026-10-21: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-10-31 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-02-18 | Drugs Made In America Acquisition LLC | ten percent owner | P | 30,000 | — | — |
| 2025-02-18 | Stockwell Lynn | director | P | 30,000 | — | — |
| 2025-02-18 | Drugs Made In America Acquisition LLC | ten percent owner | P | 30,000 | — | — |
| 2025-02-18 | Stockwell Lynn | director | P | 30,000 | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | ten percent owner | P | 400,000 | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | ten percent owner | S | 5,698,363 | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | ten percent owner | J | 400,000 | — | — |
| 2025-01-29 | Stockwell Lynn | director | S | 5,698,363 | — | — |
| 2025-01-29 | Stockwell Lynn | director | J | 400,000 | — | — |
| 2025-01-29 | Stockwell Lynn | director | P | 400,000 | — | — |
| 2025-01-29 | Shulgan Myron W. | director | J | 100,000 | — | — |
| 2025-01-29 | Prasad Sridhar G. | director | J | 100,000 | — | — |
| 2025-01-29 | Do Catherine | director | J | 100,000 | — | — |
| 2025-01-29 | Worman Glenn C. | officer | J | 100,000 | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | ten percent owner | P | 400,000 | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | ten percent owner | J | 400,000 | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | ten percent owner | S | 5,698,363 | — | — |
| 2025-01-29 | Stockwell Lynn | director | P | 400,000 | — | — |
| 2025-01-29 | Stockwell Lynn | director | J | 400,000 | — | — |
| 2025-01-29 | Stockwell Lynn | director | S | 5,698,363 | — | — |
| 2025-01-29 | Shulgan Myron W. | director | J | 100,000 | — | — |
| 2025-01-29 | Prasad Sridhar G. | director | J | 100,000 | — | — |
| 2025-01-29 | Do Catherine | director | J | 100,000 | — | — |
| 2025-01-29 | Worman Glenn C. | officer | J | 100,000 | — | — |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.
Recent filings
- 2026-10-21 8-K
- 2026-10-21 425
- 2026-09-14 8-K
- 2026-09-14 425
- 2026-08-14 10-Q
- 2026-08-14 SCHEDULE 13G/A
- 2026-08-14 SCHEDULE 13G/A
- 2026-08-13 SCHEDULE 13G/A
- 2026-08-13 SCHEDULE 13G/A
- 2026-07-20 425
- 2026-07-20 8-K
- 2026-06-26 SCHEDULE 13G
- 2026-05-14 10-Q
- 2026-05-14 SCHEDULE 13G
- 2026-05-05 425
- 2026-05-05 8-K
- 2026-05-01 8-K
- 2026-04-28 8-K
- 2026-04-16 DEFR14A
- 2026-04-15 10-K